Autoimmune Diseases
Welcome,         Profile    Billing    Logout  
 293 Companies   491 Products   491 Products   198 Mechanisms of Action   26 Trials   7806 News 


«12...1617181920212223242526...156157»
  • ||||||||||  Trial completion:  Young With Diabetes Type 1 - Test of an mHealth App (clinicaltrials.gov) -  Apr 10, 2017   
    P=N/A,  N=140, Completed, 
    Recruiting --> Completed | N=1500 --> 3258 Active, not recruiting --> Completed
  • ||||||||||  Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
    Trial withdrawal:  Topical Infliximab in Autoimmune Eyes With Keratoprosthesis (clinicaltrials.gov) -  Apr 7, 2017   
    P1/2,  N=0, Withdrawn, 
    Active, not recruiting --> Completed Enrolling by invitation --> Withdrawn
  • ||||||||||  H.P. Acthar Gel (repository corticotropin injection) / Mallinckrodt
    Enrollment change, Trial withdrawal:  Acthar on Proteinuria in IgA Nephropathy Patients (clinicaltrials.gov) -  Apr 5, 2017   
    P4,  N=0, Withdrawn, 
    Trial primary completion date: Oct 2015 --> Jan 2018 N=26 --> 0 | Recruiting --> Withdrawn
  • ||||||||||  Trial completion, Enrollment change:  Wahls Paleo Diet and Progressive Multiple Sclerosis (clinicaltrials.gov) -  Mar 31, 2017   
    P=N/A,  N=15, Completed, 
    Trial primary completion date: Apr 2014 --> Jul 2017 Active, not recruiting --> Completed | N=45 --> 15
  • ||||||||||  Trial completion, Phase classification, Trial primary completion date:  CTSM: Effects of the Cross-Training in Patients With Multiple Sclerosis (clinicaltrials.gov) -  Mar 29, 2017   
    P=N/A,  N=45, Completed, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Oct 2017 Recruiting --> Completed | Phase classification: P1/2 --> PN/A | Trial primary completion date: Apr 2016 --> Mar 2017
  • ||||||||||  Antiferon (interferon alpha kinoid) / Neovacs
    Trial completion:  Safety of IFNa Kinoid in Systemic Lupus Erythematosus (clinicaltrials.gov) -  Mar 27, 2017   
    P1/2,  N=28, Completed, 
    Recruiting --> Completed Active, not recruiting --> Completed
  • ||||||||||  Trial completion:  Safety of RG2077 in Patients With Multiple Sclerosis (clinicaltrials.gov) -  Mar 26, 2017   
    P1,  N=20, Completed, 
    Recruiting --> Completed No longer recruiting --> Completed